Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.